Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bristol-Myers signs deal with CytomX
by Ann M. Thayer
March 27, 2017
| A version of this story appeared in
Volume 95, Issue 13
Bristol-Myers Squibb and CytomX Therapeutics are expanding a drug discovery collaboration that dates back to 2014. To four ongoing projects the partners will add up to six cancer and two other drug targets using CytomX’s Probody technology. Bristol-Myers will pay $200 million up front, along with research funding and as much as $448 million in potential milestones for each new target. Probody therapeutics are designed to be activated by proteases in the tumor microenvironment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter